Sheaff Brock Investment Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 2.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,301 shares of the company’s stock after selling 871 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Johnson & Johnson were worth $3,798,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Financial Gravity Wealth Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $105,000. WP Advisors LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $108,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $117,000. Live Your Vision LLC boosted its position in shares of Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after purchasing an additional 502 shares during the period. Finally, Signition LP purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $204,000. 66.60% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently weighed in on JNJ. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Raymond James increased their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $142.54.
In other Johnson & Johnson news, insider Joaquin Duato sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the sale, the insider now directly owns 112,848 shares in the company, valued at approximately $16,290,737.28. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the sale, the chief accounting officer now owns 17,284 shares in the company, valued at $2,508,772.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,340 shares of company stock worth $11,992,396. 0.22% of the stock is owned by company insiders.
Johnson & Johnson stock opened at $145.34 on Friday. The company has a market cap of $388.35 billion, a price-to-earnings ratio of 18.21, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.90 EPS. Equities analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
COPYRIGHT VIOLATION NOTICE: “Sheaff Brock Investment Advisors LLC Has $3.80 Million Stake in Johnson & Johnson (JNJ)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/sheaff-brock-investment-advisors-llc-has-3-80-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.